Virtual Screening and Molecular Docking

Virtual screening uses computational methods to prioritize compounds for experimental follow-up. Ligand-based approaches compare candidate molecules with known actives; structure-based approaches use a target structure. Molecular docking is a structure-based method that searches for plausible ligand poses in a binding site and scores them according to an approximate energy or interaction function. A typical docking workflow prepares a protein structure and ligand representations, defines a search region, samples orientations and conformations, and ranks resulting poses. Tools such as AutoDock Vina use a scoring function and optimization procedure to estimate favorable binding arrangements. The score is a model output under specified assumptions, not a measured binding free energy. It is sensitive to protonation, tautomer choice, receptor conformation, solvent treatment, and the search box. Virtual screening can help reduce an enormous chemical catalog to candidates worth closer inspection. Enrichment tests ask whether known actives rank above decoys or inactives under a defined benchmark. But retrospective enrichment can be inflated by data leakage, scaffold similarity, or an unrealistic decoy set. Use scaffold-aware splits and external test sets when evaluating predictive workflows. Docking is not a substitute for molecular dynamics, binding experiments, or cell assays. A plausible pose can still represent a false positive; a poor score can miss a real binder. Proteins move, water molecules and cofactors matter, and assay conditions may differ from a static structure. Consider chemical feasibility, solubility, synthesis, selectivity, toxicity, and experimental reproducibility after computational ranking. The best use is triage. Combine structure-based scores with ligand-based models, human review, orthogonal assays, and portfolio diversity. Track each prediction's structure source, preparation settings, model, and rationale so results can be reproduced. Present a score as evidence for prioritization, never as proof that a compound will become a drug.